04.25.17
Domain Therapeutics, a biopharma company specializing in new drug candidates that target G protein-coupled receptors (GPCRs), has entered a collaboration agreement with Pfizer to assess the impact of mutations on different signaling pathways engaged by GPCRs. Domain will use its bioSensAll technology to define signaling signatures for each of the wild-type and mutant receptors.
The bioSensAll technology allows for easier understanding of signaling pathways activated by each candidate molecule, predicting its pharmacological profile. This makes it possible to choose at an early stage molecules that have the required activity but do not present side effects or induce tolerance to treatment.
The collaboration aims to validate potential targets across a range of therapeutic indications. Pfizer will use the results of specific mutations on intracellular signaling to guide further investigations in disease-specific models.
“We are very pleased to have signed this collaboration with Pfizer for the profiling of mutant GPCRs using the bioSensAll platform. It is yet another example of the wide applications of the technology, from target validation through to drug discovery and development,” said Pascal Neuville, chief executive officer of Domain Therapeutics. “By building a better understanding of the signaling profile needed for efficacy, bioSensAll may reduce the attrition rate of early-stage drug development.”
The bioSensAll technology allows for easier understanding of signaling pathways activated by each candidate molecule, predicting its pharmacological profile. This makes it possible to choose at an early stage molecules that have the required activity but do not present side effects or induce tolerance to treatment.
The collaboration aims to validate potential targets across a range of therapeutic indications. Pfizer will use the results of specific mutations on intracellular signaling to guide further investigations in disease-specific models.
“We are very pleased to have signed this collaboration with Pfizer for the profiling of mutant GPCRs using the bioSensAll platform. It is yet another example of the wide applications of the technology, from target validation through to drug discovery and development,” said Pascal Neuville, chief executive officer of Domain Therapeutics. “By building a better understanding of the signaling profile needed for efficacy, bioSensAll may reduce the attrition rate of early-stage drug development.”
